货号:A208987 同义名: Daunomycin;RP 13057
Daunorubicin, a topoisomerase II inhibitor, inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM.
There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | DNA synthesis ↓ ↑ | helicase ↓ ↑ | RdRp ↓ ↑ | ribonucleotide reductase ↓ ↑ | tRNA synthetase ↓ ↑ | YB-1 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fexinidazole | ✔ | 98% | |||||||||||||||||
Daptomycin | ✔ | 98% | |||||||||||||||||
Blasticidin S·HCl | ✔ | 98% | |||||||||||||||||
Metronidazole | ✔ | 98% | |||||||||||||||||
Daunorubicin HCl |
+++
DNA synthesis, Ki: 20 nM |
98% | |||||||||||||||||
Triglycidyl isocyanurate | ✔ | p53 | 98+% | ||||||||||||||||
Nedaplatin | ✔ | 99%+ | |||||||||||||||||
Bendamustine | ✔ | 98+% | |||||||||||||||||
Trifluridine | ✔ | 98% | |||||||||||||||||
Robinetin | ✔ | 99%+ | |||||||||||||||||
Carboplatin | ✔ | 99% | |||||||||||||||||
Cidofovir | ✔ | 99% | |||||||||||||||||
Cisplatin | ✔ | 99% | |||||||||||||||||
Cytarabine |
++++
DNA synthesis, IC50: 16 nM |
98% | |||||||||||||||||
Acelarin |
++++
DNA synthesis, EC50: 0.2 nM |
99%+ | |||||||||||||||||
Oxaliplatin | ✔ | 98% | |||||||||||||||||
YK-4-279 | ✔ | 99%+ | |||||||||||||||||
ML216 |
+
BLMfull-length, IC50: 2.98 μM BLM636-1298, IC50: 0.97 μM |
99%+ | |||||||||||||||||
RK-33 | ✔ | 98% | |||||||||||||||||
Brr2-IN-3 | ✔ | 99%+ | |||||||||||||||||
Phen-DC3 Trifluoromethanesulfonate | ✔ | 98% | |||||||||||||||||
Favipiravir | ✔ | 97% | |||||||||||||||||
Suramin sodium salt |
++
RdRp, IC50: 0.26 μM |
99%+ | |||||||||||||||||
Clofarabine |
++
Ribonucleotide reductase, IC50: 65 nM |
97% | |||||||||||||||||
Didox | ✔ | 98% | |||||||||||||||||
(E)-3-AP | ✔ | 97% | |||||||||||||||||
Halofuginone |
+++
prolyl-tRNA synthetase, Ki: 18.3nM |
99%+ | |||||||||||||||||
BC-LI-0186 |
+++
Leucyl-tRNA synthetase, Kd: 42.1 nM Leucyl-tRNA synthetase, IC50: 46.11 nM |
98% | |||||||||||||||||
SU056 |
+
YB-1, IC50: 1.73 μM |
98% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | Autophagy ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SBI-0206965 |
+++
ULK2, IC50: 711 nM ULK1, IC50: 108 nM |
97% | |||||||||||||||||
Hydroxychloroquine sulfate | ✔ | 99% | |||||||||||||||||
Valproic acid sodium | ✔ | HDAC | 97% | ||||||||||||||||
PFK-015 |
++
PFKFB3, IC50: 207 nM |
99%+ | |||||||||||||||||
MRT68921 hydrochloride |
++++
ULK2, IC50: 1.1 nM ULK1, IC50: 2.9 nM |
99%+ | |||||||||||||||||
ROC-325 | ✔ | 99%+ | |||||||||||||||||
Autophinib |
+++
Autophagy, IC50: 40 nM |
97% | |||||||||||||||||
Lys05 | ✔ | 99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | Topo I ↓ ↑ | Topo II ↓ ↑ | Topo IV ↓ ↑ | Topoisomerase ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ellagic acid | ✔ | 98% | |||||||||||||||||
β-Lapachone | ✔ | 99%+ | |||||||||||||||||
(s)-10-hydroxycamptothecin | ✔ | 98+% | |||||||||||||||||
Camptothecin |
++
Topo I, IC50: 0.68 μM |
98% | |||||||||||||||||
Betulinic acid |
++
Eukaryotic topoisomerase I, IC50: 5 μM |
98% | |||||||||||||||||
Topotecan |
++++
Topo I (MCF-7 Luc cells), IC50: 13 nM Topo I (DU-145 Luc cells), IC50: 2 nM |
98% | |||||||||||||||||
Irinotecan HCl Trihydrate | ✔ | 98% | |||||||||||||||||
SN-38 | ✔ | 98% | |||||||||||||||||
Levofloxacin hydrate | ✔ | 98% | |||||||||||||||||
Dexrazoxane | ✔ | 99%+ | |||||||||||||||||
Ofloxacin | ✔ | 98+% | |||||||||||||||||
Enoxacin | ✔ | 99%+ | |||||||||||||||||
Flumequine |
+
Topo II, IC50: 15 μM |
98% | |||||||||||||||||
Levofloxacin | ✔ | 97% | |||||||||||||||||
Etoposide | ✔ | 98% | |||||||||||||||||
Pefloxacin mesylate dihydrate | ✔ | 99+% | |||||||||||||||||
Marbofloxacin | ✔ | 98+% | |||||||||||||||||
Voreloxin HCl | ✔ | 98% | |||||||||||||||||
Mitoxantrone dihydrochloride | ✔ | PKC | 98% | ||||||||||||||||
Nalidixic acid | ✔ | 98% | |||||||||||||||||
Doxorubicin | ✔ | 98% | |||||||||||||||||
Novobiocin sodium | ✔ | 95% | |||||||||||||||||
Amonafide | ✔ | 99%+ | |||||||||||||||||
Pirarubicin | ✔ | 98%+ | |||||||||||||||||
Idarubicin HCl |
+++
Topo II (MCF-7 cells), IC50: 3.3 ng/mL |
99%+ | |||||||||||||||||
Genistein | ✔ | EGFR | 98% | ||||||||||||||||
Teniposide | ✔ | 98% | |||||||||||||||||
Moxifloxacin | ✔ | 98% | |||||||||||||||||
Ciprofloxacin | ✔ | 98% | |||||||||||||||||
Clinafloxacin | ✔ | 97% | |||||||||||||||||
Gatifloxacin | ✔ | 98% | |||||||||||||||||
Daunorubicin HCl |
+++
DNA synthesis, Ki: 20 nM |
98% | |||||||||||||||||
Epirubicin HCl | ✔ | 99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | Daunorubicin, a topoisomerase II inhibitor, inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02198482 | Acute Myeloid Leukemia (AML) ... 展开 >> High-risk Myelodysplastic Syndrome (MDS) 收起 << | Phase 2 | Terminated(development program... 展开 >> of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems) 收起 << | - | Germany ... 展开 >> Hospital Aschaffenburg Aschaffenburg, Germany, 63739 Helios Hospital Bad Saarow Bad Saarow, Germany, 15526 Vivantes Hospital Am Urban Berlin, Germany, 10967 Vivantes Hospital Neukölln Berlin, Germany, 12351 Charite Berlin Campus Virchow Hospital Berlin, Germany, 13353 Knappschaftskrankenhaus Bochum-Langendeer Bochum, Germany, 44892 University Hospital Bonn Bonn, Germany, 53105 Community Hospital Braunschweig Braunschweig, Germany, 38114 Hospital Darmstadt Darmstadt, Germany, 64283 University Hospital Düsseldorf Düsseldorf, Germany, 40225 Hospital Essen, Protestant Hospital Essen-Werden Essen, Germany, 45239 Hospital Esslingen Esslingen, Germany, 73730 Malteser Hospital St. Franziskus Flensburg, Germany, 24939 Hospital Frankfurt-Höchst Frankfurt, Germany, 65929 Medical Care Unit Osthessen Fulda, Germany, 36043 University Hospital Gießen Gießen, Germany, 35392 Wilhelm-Anton-Hospital Goch Goch, Germany, 47574 University Hospital Göttingen Göttingen, Germany, 37075 University Hospital Hamburg-Eppendorf Hamburg, Germany, 20246 Asklepios Hospital Altona Hamburg, Germany, 22763 Hospital Hanau Hanau, Germany, 63450 KRH Hospital Siloah-Oststadt-Heidehaus Hannover, Germany, 30459 Hannover Medical School Hannover, Germany, 30625 SLK-Hospital Heilbronn Heilbronn, Germany, 74078 Marienhospital Herne Herne, Germany, 44625 University Hospital des Saarlandes Homburg/Saar, Germany, 66421 Community Hospital Karlsruhe Karlsruhe, Germany, 76133 University Hospital Schleswig-Holstein Kiel, Germany, 24105 Caritas Hospital Lebach Lebach, Germany, 66822 Hospital Lippe-Lemgo Lemgo, Germany, 32657 University Hospital Magdeburg Magdeburg, Germany, 39120 University Hospital Johannes Gutenberg Mainz Mainz, Germany, 55131 Johannes Wesling Hospital Minden Minden, Germany, 32429 Stauferklinikum Schwäbisch-Gmünd Mutlangen, Germany, 73557 Hospital Schwabing München, Germany, 80804 Hospital rechts der Isar München München, Germany, 81675 Hospital Oldenburg Oldenburg, Germany, 26133 Hospital Passau Passau, Germany, 94032 Hospital Stuttgart Stuttgart, Germany, 70174 Diakonie Hospital Stuttgart Stuttgart, Germany, 70176 Hospital Traunstein Traunstein, Germany, 83278 Mutterhaus der Borromäerinnen Trier, Germany, 54290 Hospital Barmherzige Brüder Trier Trier, Germany, 54292 University Hospital Tübingen Tübingen, Germany, 72076 University Hospital Ulm Ulm, Germany, 89081 收起 << |
NCT02236013 | Acute Myeloid Leukemia | Phase 1 | Recruiting | July 2022 | United States, California ... 展开 >> Site US10003 Recruiting Los Angeles, California, United States, 90095 United States, Connecticut Site US10013 Recruiting New Haven, Connecticut, United States, 06520 United States, Illinois Site US10004 Recruiting Chicago, Illinois, United States, 60611 United States, Kansas Site US10009 Recruiting Westwood, Kansas, United States, 66205 United States, Maryland Site US10001 Recruiting Baltimore, Maryland, United States, 21231 United States, New York Site US10002 Recruiting New York, New York, United States, 10032 United States, Ohio Site US10014 Recruiting Cleveland, Ohio, United States, 44106 Site US10008 Withdrawn Columbus, Ohio, United States, 43201 United States, Oklahoma Site US10019 Recruiting Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Site US10006 Recruiting Philadelphia, Pennsylvania, United States, 19104 United States, Texas Site US10010 Recruiting San Antonio, Texas, United States, 78229 收起 << |
NCT00037583 | Acute Myeloid Leukemia | Phase 2 | Completed | - | - |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.90mL 0.38mL 0.19mL |
9.48mL 1.90mL 0.95mL |
18.96mL 3.79mL 1.90mL |
CAS号 | 20830-81-3 |
分子式 | C27H29NO10 |
分子量 | 527.52 |
别名 | Daunomycin;RP 13057;Rubidomycin |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Sealed in dry,2-8°C |
溶解度 | |
动物实验配方 |